ESG

Croatian firm Orqa is building a global network to produce one million drones annually, challenging market leaders and securing allied defense supply chains.

Chinese insurtech Huize is cutting back on financial reports to focus on strategy, but its latest data shows a complex picture of soaring premiums and slowing new user growth.

A unique partnership brings accessible genetic testing to Boca Raton, using a community race to empower families with critical health knowledge.

Fourth-generation farmer John Melo brings large-scale operational expertise to the Dairy Council, poised to shape California's dairy sustainability and health initiatives.

A new class action lawsuit accuses medical device firm Integer Holdings of hiding poor sales while touting growth, leading to a major stock drop.

Mirum raises over a quarter-billion dollars to acquire Bluejay Therapeutics, targeting a high-potential liver disease drug and signaling major growth.

A landmark executive order to reschedule cannabis and create a Medicare CBD program could unleash a $30B market and redefine the economics of the industry.

In a landmark deal, BioMarin acquires Amicus Therapeutics, gaining high-growth drugs and reshaping the landscape for patients with rare genetic disorders.

Loyola Marymount University is expanding its EV charging with ChargePoint's AI platform and maintenance service, creating a reliable network for its community.

A landmark executive order reclassifying cannabis is set to unleash a wave of biopharma innovation, validating science-first firms like Avicanna.

A strategic partnership aims to merge respiratory rentals with innovative hygiene products, promising better compliance and comfort for millions of CPAP users.

A new settlement positions a cost-effective alternative to the blockbuster eye drug Eylea for a 2026 U.S. launch, signaling intense market disruption.

A new joint venture aims to redefine Tallinn's skyline with a potential 60-storey high-rise, part of a major expansion in the Manufaktuuri quarter.

The CEO of Genenta Science now owns 10% of the company, all bought on the open market. What does this bold insider move signal for its cancer therapy?

CLO Virtual Fashion launches a Dongguan hub, integrating its massive digital fabric library to transform the global apparel supply chain from the source.

Researchers at Kanazawa University have developed engineered nanoparticles that can reprogram rogue immune cells, offering a targeted therapy for autoimmune diseases.

With backing from AstraZeneca and Pfizer, Beijing’s Syneron Bio is using its AI-driven platform to develop novel drugs for cancer and chronic illness.

In a major move for the AI infrastructure race, TeraWulf and Fluidstack secure massive project financing for a 168 MW Texas facility, backed by Google.

In a fierce biotech talent war, Senti Bio's new equity grant for a key hire signals a strategic push for its gene therapy pipeline amid market volatility.

A new oral drug, cadisegliatin, enters a major clinical trial in the UAE, aiming to help Type 2 diabetes patients struggling with insulin therapy.